Marso SP, et al. - In the LEADER trial, it was shown that liraglutide significantly reduced the risk of major adverse cardiovascular (CV) events [composite of CV death, non-fatal myocardial infarction (MI) or non-fatal stroke] vs placebo in patients with type 2 diabetes mellitus (DM) and high CV risk. This study represents a post hoc analysis to characterize MIs (first and recurrent) occurring in LEADER, by treatment arm and regarding incidence, outcome, subtype and troponin levels. Findings of this investigation demonstrated liraglutide-induced reduction in the incidence of MIs in patients with type 2 DM at high CV risk. Also, liraglutide may effect the clinical outcomes of MI.